{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:48:51Z","timestamp":1781801331998,"version":"3.54.5"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.cllc.2020.11.002","type":"journal-article","created":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T21:06:45Z","timestamp":1605560805000},"page":"e512-e518","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["MET Amplification (MET\/CEP7 Ratio\u00a0\u2265 1.8) Is an Independent Poor Prognostic Marker in Patients With Treatment-naive Non\u2013Small-cell Lung Cancer"],"prefix":"10.1016","volume":"22","author":[{"given":"Wei","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenya","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5305-6337","authenticated-orcid":false,"given":"Gokce","family":"Toruner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7110-3814","authenticated-orcid":false,"given":"Shimin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9134-8632","authenticated-orcid":false,"given":"Melissa","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2020.11.002_bib1","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.cllc.2020.11.002_bib2","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2020.11.002_bib3","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1080\/14737140.2020.1787156","article-title":"Molecular therapeutic targets in non-small cell lung cancer","volume":"20","author":"Sankar","year":"2020","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.cllc.2020.11.002_bib4","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jtho.2016.06.004","article-title":"Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations","volume":"11","author":"Schrock","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2020.11.002_bib5","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1158\/2159-8290.CD-14-1467","article-title":"Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping","volume":"5","author":"Paik","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cllc.2020.11.002_bib6","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1080\/10408363.2019.1653821","article-title":"HGF\/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers","volume":"56","author":"Moosavi","year":"2019","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.cllc.2020.11.002_bib7","doi-asserted-by":"crossref","first-page":"e99399","DOI":"10.1371\/journal.pone.0099399","article-title":"Prognostic value of MET gene copy number and protein expression in patients with surgically resected non-small cell lung cancer: a meta-analysis of published literatures","volume":"9","author":"Guo","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cllc.2020.11.002_bib8","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/j.cllc.2016.01.005","article-title":"Prognostic impact of multiple clinicopathologic risk factors and c-MET overexpression in patients who have undergone resection of stage IB non\u2013small-cell lung cancer","volume":"17","author":"Kim","year":"2016","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2020.11.002_bib9","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/JTO.0b013e3181ce3d1d","article-title":"High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer","volume":"5","author":"Go","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2020.11.002_bib10","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1200\/JCO.2008.19.1635","article-title":"Increased MET gene copy number negatively affects survival of surgically resected non\u2013small-cell lung cancer patients","volume":"27","author":"Cappuzzo","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.11.002_bib11","doi-asserted-by":"crossref","first-page":"12959","DOI":"10.18632\/oncotarget.24430","article-title":"MET amplification assessed using optimized FISH reporting criteria predicts early distant metastasis in patients with non-small cell lung cancer","volume":"9","author":"Fang","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.cllc.2020.11.002_bib12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2009.11.022","article-title":"Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC","volume":"17","author":"Turke","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cllc.2020.11.002_bib13","doi-asserted-by":"crossref","first-page":"20932","DOI":"10.1073\/pnas.0710370104","article-title":"MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib","volume":"104","author":"Bean","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cllc.2020.11.002_bib14","doi-asserted-by":"crossref","first-page":"9020","DOI":"10.1200\/JCO.2017.35.15_suppl.9020","article-title":"MET amplification (amp) is a major resistance mechanism to osimertinib","volume":"35","author":"Piotrowska","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.11.002_bib15","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.cllc.2020.11.002_bib16","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1097\/JTO.0b013e31821528d3","article-title":"Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification","volume":"6","author":"Ou","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2020.11.002_bib17","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1177\/1078155219851853","article-title":"An advanced c-MET-amplified NSCLC patient that was treated with crizotinib","volume":"26","author":"Yilmaz","year":"2020","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.cllc.2020.11.002_bib18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jtho.2016.10.014","article-title":"Targeting MET in lung cancer: will expectations finally be MET?","volume":"12","author":"Drilon","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2020.11.002_bib19","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/JTO.0b013e318240ca0d","article-title":"Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer","volume":"7","author":"Dziadziuszko","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2020.11.002_bib20","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.3390\/cancers6031540","article-title":"Targeting MET amplification as a new oncogenic driver","volume":"6","author":"Kawakami","year":"2014","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cllc.2020.11.002_bib21","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.18632\/oncotarget.1906","article-title":"Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1\/carboplatin versus paclitaxel\/carboplatin: results of a West Japan Oncology Group study","volume":"5","author":"Okamoto","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.cllc.2020.11.002_bib22","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jtho.2019.06.009","article-title":"MET IHC is a poor screen for MET amplification or MET exon 14 mutations in lung adenocarcinomas: data from a tri-institutional cohort of the Lung Cancer Mutation Consortium","volume":"14","author":"Guo","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2020.11.002_bib23","doi-asserted-by":"crossref","first-page":"5581","DOI":"10.1158\/1078-0432.CCR-10-0851","article-title":"Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment","volume":"16","author":"Camidge","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2020.11.002_bib24","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1200\/JCO.18.00177","article-title":"Clonal MET amplification as a determinant of tyrosine kinase inhibitor resistance in epidermal growth factor receptor-mutant non-small-cell lung cancer","volume":"37","author":"Lai","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.11.002_bib25","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jtho.2016.04.033","article-title":"Identifying the appropriate FISH criteria for defining MET copy number-driven lung adenocarcinoma through oncogene overlap analysis","volume":"11","author":"Noonan","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2020.11.002_bib26","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1158\/1078-0432.CCR-14-0450","article-title":"MET amplification status in therapy-naive adeno- and squamous cell carcinomas of the lung","volume":"21","author":"Schildhaus","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2020.11.002_bib27","first-page":"197","article-title":"High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients","volume":"27","author":"Park","year":"2012","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.cllc.2020.11.002_bib28","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/j.jtho.2018.08.008","article-title":"c-MET overexpression as a poor predictor of MET amplifications or exon 14 mutations in lung sarcomatoid carcinomas","volume":"13","author":"Mignard","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2020.11.002_bib29","doi-asserted-by":"crossref","first-page":"167","DOI":"10.21037\/tlcr.2019.03.11","article-title":"Mesenchyme to epithelial transition protein expression, gene copy number and clinical outcome in a large non-small cell lung cancer surgical cohort","volume":"8","author":"Rivalland","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.cllc.2020.11.002_bib30","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/PAT.0000000000000269","article-title":"Correlation between MET protein expression and MET gene copy number in a Caucasian cohort of non-small cell lung cancers according to the new IASLC\/ATS\/ERS classification","volume":"47","author":"Weingertner","year":"2015","journal-title":"Pathology"},{"key":"10.1016\/j.cllc.2020.11.002_bib31","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.lungcan.2017.07.021","article-title":"Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: results from the European Thoracic Oncology Platform (ETOP) Lungscape project","volume":"111","author":"Bubendorf","year":"2017","journal-title":"Lung Cancer"},{"issue":"suppl","key":"10.1016\/j.cllc.2020.11.002_bib32","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.1200\/jco.2014.32.15_suppl.8001","article-title":"Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC)","volume":"32","author":"Camidge","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.11.002_bib33","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1535-6108(02)00017-X","article-title":"A\u00a0role for common fragile site induction in amplification of human oncogenes","volume":"1","author":"Hellman","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cllc.2020.11.002_bib34","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1158\/1078-0432.CCR-15-2061","article-title":"MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis","volume":"22","author":"Tong","year":"2016","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730420303351?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730420303351?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:13:10Z","timestamp":1761505990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730420303351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S1525730420303351"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2020.11.002","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MET Amplification (MET\/CEP7 Ratio\u00a0\u2265 1.8) Is an Independent Poor Prognostic Marker in Patients With Treatment-naive Non\u2013Small-cell Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2020.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}